Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer

Journal of Clinical Oncology

Volumn 27, Issue 9, 2009, Pages 1401-1404

  Lau, Derick ^a   Chen, Gigi ^a   Huynh, Minh ^a   Fehrenbacher, Lou ^a   West, Howard ^a   Lara Jr , Primo N ^a   Yavorkovsky, Leonid L ^a   Russin, Michael ^a   Goldstein, Desiree ^a   Gandara, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 63049136369     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.2127     Document Type: Article

References (17)

1. Chute JP, Chen T, Feigal E, et al: Twenty years of phase III trials for patients with extensivestage small-cell lung cancer: Perceptible progress. J Clin Oncol 17:1794-1801, 1999
2. Sundstrøm S, Bremnes RM, Kaasa S, et al: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20:4665-4672, 2002
3. von Pawel J, Schiller JH, Sheperd FA, et al: Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 17:658-667, 1999
4. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
5. Natale RB, Lara PN, Chansky K, et al: S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol 26: 400s, 2008 (suppl; abstr 7512)
6. Skarlos DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin vs etoposide carboplatin and irradiation in small cell lung cancer Hellenic Co-operation Oncology Group Study. Ann Oncol 5:601-607, 1994
7. Sohn JH, Choi HJ, Chang J, et al: A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive stage small cell lung cancer. Lung Cancer 54:365-370, 2006
8. Schmittel A, Fischer von Weikersthal L, et al: A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small cell lung cancer. Ann Oncol 17:663-667, 2006
9. Wild C, Wang S, Gandara D, et al: Populationbased maximum tolerated dose of irinotecan and carboplatin. Oncology 17:11-16, 2003
10. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
11. James K, Eisenhauer E, Christian M, et al: Measuring response in solid tumors: Unidimensional versus bidimensional measurement. J Natl Cancer Inst 91:523-528, 1999
12. Chen G, Huynh M, Chen A, et al: Chemotherapy for brain metastasis in small-cell lung cancer. Clin Lung Cancer 9:35-38, 2008
13. Hermes A, Bergman B, Bremnes R, et al: Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial. J Clin Oncol 26:4261-4267, 2008
14. O'Brien M, Ciuleanu T, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24: 5441-5447, 2006
15. Ettinger DS, Jotte RM, Gupta V, et al: A phase II trial of single-agent amrubicin (AMR) in patients with extensive small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy. J Clin Oncol 26:434s, 2008 (suppl; abstr 8041)
16. Jotte RM, Conkling PR, Reynolds C, et al: A randomized phase II trial of amrubicin (AMR) vs topotecan as second-line treatment in extensivedisease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. J Clin Oncol 26:433s, 2008 (suppl; abstr 8040)
17. Onoda S, Masuda N, Seto T, et al: Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 24:5448-5453, 2006